Full text
PDFPage 606
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gruzelier J., Thornton S., Staniforth D., Zaki S., Yorkston N. Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics. Br J Psychiatry. 1980 Aug;137:131–137. doi: 10.1192/bjp.137.2.131. [DOI] [PubMed] [Google Scholar]
- Hanssen T., Heyden T., Sundberg I., Alfredsson G., Nybäck H., Wetterberg L. Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings. Arch Gen Psychiatry. 1980 Jun;37(6):685–690. doi: 10.1001/archpsyc.1980.01780190083010. [DOI] [PubMed] [Google Scholar]
- Leszkovszky G., Tardos L. Some effects of propranolol on the central nervous system. J Pharm Pharmacol. 1965 Aug;17(8):518–519. doi: 10.1111/j.2042-7158.1965.tb07715.x. [DOI] [PubMed] [Google Scholar]
- Lindström L. H., Persson E. Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients. Br J Psychiatry. 1980 Aug;137:126–130. doi: 10.1192/bjp.137.2.126. [DOI] [PubMed] [Google Scholar]
- Sheppard G. P. High-dose propranolol in schizophrenia. Br J Psychiatry. 1979 May;134:470–476. doi: 10.1192/bjp.134.5.470. [DOI] [PubMed] [Google Scholar]
- WING L., LADER M. H. PHYSIOLOGICAL AND CLINICAL EFFECTS OF AMYLOBARBITONE SODIUM THERAPY IN PATIENTS WITH ANXIETY STATES. J Neurol Neurosurg Psychiatry. 1965 Feb;28:78–87. doi: 10.1136/jnnp.28.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yorkston N. J., Zaki S. A., Pitcher D. R., Gruzelier J. H., Hollander D., Sergeant H. G. Propranolol as an adjunct to the treatment of schizophrenia. Lancet. 1977 Sep 17;2(8038):575–578. doi: 10.1016/s0140-6736(77)91427-1. [DOI] [PubMed] [Google Scholar]